参考文献
[1] 韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志 2013,18:330-334. DOI:10.3969/j.issn.1009-0460.2013.04.009.
[2] Tannock IF, de Wit R, Berry WR,et al. Docetaxel plus prednisone or mitox-antrone plus prednisone for advanced prostate cancer[J]. N Engl J Med,2004,351:1502-1512.
[3] de Bono JS, Logothetis CJ, Molina A,et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N Engl J Med,2011,364:1995-2005. DOI:10.1056/NEJMoa1014618.
[4] Scher HI, Fizazi K, Saad F,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med,2012,367:1187-1197. DOI:10.1056/NEJMoa1207506.
[5] Parker C, Nilsson S, Heinrich D,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med,2013,369:213-223. DOI:10.1056/NEJMoa1213755.
[6] 胡林军,李长岭,寿建忠,等. 改良多西他赛方案治疗化疗耐受性差的前列腺癌患者的疗效和安全性[J] 中华泌尿外科杂志,2017,38:615-618. DOI:10.3760/cma.j.issn.1000-6702.2017.08.013.
[7] Kenmotsu H, Tanigawara Y. Pharmacokinetics,dynamics and toxicity of docetaxel:Why the Japanese dose differs from the Western dose[J]. Cancer Sci,2015,106:497-504.DOI:10.1111/cas.12647.
[8] 陈卓,王芳,李林,等.多西他赛血液毒性人群间差异回顾分析及临床观察[J]. 肿瘤基础与临床,2016,29:68-70.DOI:10.3969/j.issn.1673-5412.2016.01.021.
[9] 翟元元,戴波,孔藴毅,等.多西他赛联合泼尼松治疗转移性去势抵抗性前列腺癌的临床分析[J].中华泌尿外科杂志,2013,34:505-508. DOI:10.3760/cma.j.issn.1000-6702.2013.07.008.
[10] 范欣荣,李汉忠,李永强,等. 转移性去势抵抗性前列腺癌的长期化疗观察研究[J].中华泌尿外科杂志,2013,34:885-890.DOI:10.3760/cma.j.issn.1000-6702.2013.12.001.
[11] 杨恺惟,虞巍,宋毅,等.影响多西他赛联合泼尼松治疗转移性去势抵抗性前列腺癌疗效的因素分析[J].北京大学学报(医学版),2015,47:592-596. DOI:10.3969/j.issn.1671-167X.2015.04.0008.
[12] 那彦群,叶章群,曹登峰,等. 前列腺癌诊断治疗指南[M]//那彦群,叶章群,孙颖浩,等. 中国泌尿外科疾病诊断治疗指南.2014版.北京:人民卫生出版社,2013:80.
[13] 胡林军,田军,李长岭,等. 前列腺癌多西他赛化疗出现前列腺特异性抗原一过性升高现象75例临床分析[J].中国临床医生杂志,2017,45:69-71.DOI:10.3969/j.issn.2095-8552.2017.05.025.
[14] Scher HI, Halabi S, Tannock I,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:recommendations of the Prostate Cancer Clinical Trials Working Group[J].J Clin Oncol,2008,26:1148-1159. DOI: 10.1200/JCO.2007.12.4487.
[15] 罗健,罗杨.癌症疼痛和姑息治疗[M]//孙燕,石远凯.临床肿瘤内科手册.第6版.北京:人民卫生出版社,2015:200-229.
[16] 石远凯,孙燕.抗肿瘤药物的不良反应及其处理[M]//孙燕,石远凯.临床肿瘤内科手册.第6版.北京:人民卫生出版社,2015:88-95.
[17] Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T,et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer:a randomised,phase 3 trial[J]. Lancet Oncol,2013,14:117-124.DOI:10.1016/S1470-2045(12)70537-5.
[18] Zhou T, Zeng SX, Ye DW,et al. A multicenter,randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer[J]. PLoS One,2015,27:e0117002. DOI:10.1371/journal.pone.0117002.
[19] Kamiya N, Suzuki H, Ueda T,et al. Clinical Outcomes by relative docetaxel dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer:a retrospective multi-institutional collaborative study[J]. Int J Clin Oncol,2014,19:157-164. DOI:10.1007/s10147-012-0510-9.
[20] Shiota M, Yokomizo A, Takeuchi A,et al. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer[J].Support Care Cancer,2014,22:3219-3226.
[21] Kongsted P, Svane IM, Lindberg H,et al. Predictors of chemotherapy-induced toxicity and treatment outcomes in elderly versus younger patients with metastatic castration-resistant prostate cancer[J]. Clin Genitourin Cancer,2016,14:e559-e568. DOI: 10.1016/j.clgc.2016.03.018.